Physician profile
Abir Assaad Marcus
NPI 1467545079
$1,396.33
in general payments reported to CMS, 2019-2025
16 companies · $237 in 2025
The $237 reported for 2025 was more than what a typical Addiction Psychiatry provider received nationally (typical 2025 total: $127).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $427 · 2020: $187 · 2021: $75.10 · 2022: $168 · 2023: $159 · 2024: $145 · 2025: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $540.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $540.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $319.57 | 2021-2024 | |
| Lundbeck LLC | $306.30 | 2019-2025 | Rexulti |
| Axsome Therapeutics, INC. | $161.05 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $146.32 | 2019-2025 | Rexulti |
| Allergan, INC. | $144.58 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.72 | 2019-2021 | |
| Indivior INC. | $29.45 | 2020-2025 | Sublocade |
| Sunovion Pharmaceuticals INC. | $27.46 | 2019 | |
| Revance Therapeutics, INC. | $25.78 | 2024 | Daxxify |
| Jazz Pharmaceuticals INC. | $24.93 | 2019-2021 | |
| Shire North American Group INC | $23.14 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.54 | 2023 | Austedo |
| Avadel Cns Pharmaceuticals, LLC | $13.75 | 2023 | Lumryz |
| Braeburn INC. | $13.09 | 2024 | Brixadi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $12.50 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abir Marcus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.